Biotica Seeking Patent for New Class of Hepatitis C Drug
Share
Follow Us
Biotica breakthough in Hepatitis C virus
Monday, 24 October 2011
Biotica has identified a potential research breakthrough in the area of Hepatitis C virus (HCV) infection.
It has backed its confidence with a patent application and believes it is operating in clear space to commercialise the findings. The company, based at Chesterford Research Park near Cambridge UK, discovers and develops polyketide therapeutics.
It has announced the publication of a peer-reviewed article in Medicinal Chemistry Communications and of a patent application describing Sangamides, a new class of cyclophilin-inhibiting host-targeted antivirals for treatment of HCV.
Continue reading this entire article:
http://www.businessweekly.co.uk/biomedtech-/12936-biotica-breakthough-in-hepatitis-c-virus
